Castle Biosciences Inc

Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Castle Biosciences posts robust Q4 earnings, eyes growth opportunities ahead

Castle Biosciences reported strong financial performance in Q4 and full-year 2022, driven by revenue growth and test volume increase.
The company's focus on expanding commercial teams, R&D initiatives, and new laboratory openings positions it for future growth.
Challenges lie in convincing commercial payers and maintaining gross margin, requiring strategic actions and evidence-based outcomes.
Opportunities exist in demonstrating patient outcomes, NCCN guideline inclusion, and leveraging cash reserves for growth.

Castle Biosciences reports robust Q1 performance and navigates growth challenges

Castle Biosciences delivered a strong Q1 2023 with notable revenue growth and volume increases, supported by a solid financial position.
The company's focus on dermatology, gastroenterology, and mental health segments, along with positive clinical study results, underpin its market strength.
While facing challenges in sales execution and territory management, Castle Biosciences is strategically positioned to capitalize on growth opportunities in its key product lines.

Castle Biosciences reports robust Q2 growth and navigates coverage challenges

Castle Biosciences delivered strong financial performance in Q2 2023, with revenue and test volume growth surpassing expectations.
Despite challenges in coverage and operational constraints, the company's strategic focus on test value and market expansion presents promising growth prospects.
With a solid financial position, ongoing efforts to address challenges, and capitalize on opportunities, Castle Biosciences is poised for continued success in the precision medicine market.

Castle Biosciences reports stellar Q3 results and eyes market expansion

Castle Biosciences delivered exceptional financial results, raised revenue guidance, and showcased strong growth across its test portfolio. The company's focus on innovation, clinical impact, and market recognition positions it well for future success. While challenges in managing growth and competition exist, Castle Biosciences has opportunities to capitalize on its strengths and expand its market presence.

Castle Biosciences reports stellar 2023 performance and eyes new markets

Castle Biosciences delivered strong financial performance in Q4 and full year 2023, driven by robust revenue growth and impressive test volume results across key tests.
The company showcased clinical efficacy, innovation, and financial discipline, while navigating challenges such as cost pressures and reimbursement uncertainties.
Strategic initiatives like expanding test portfolios, managing costs effectively, and exploring new growth avenues position Castle Biosciences for continued success and market leadership.
With a focus on maintaining profitability, investing in growth, and leveraging opportunities, Castle Biosciences is poised for sustained growth and value creation in the future.

Castle Biosciences excels in Q1 2024, eyes strategic growth opportunities

Castle Biosciences delivered exceptional financial and operational results in Q1 2024, showcasing strong revenue growth, improved margins, and product advancements. While facing some challenges with test volumes and Medicare coverage, the company's solid performance and market position present promising opportunities for future growth.

Castle Biosciences excels in Q2, raises guidance amid test volume surge

Castle Biosciences delivered outstanding financial results in Q2 2024, showcasing strong revenue growth, improved margins, and a significant net income turnaround.
The company's focus on innovation and clinical value in its tests positions it well for sustained growth and market leadership in precision diagnostics.
While facing challenges in maintaining growth momentum and operational efficiency, Castle Biosciences has opportunities to expand its market presence and drive international expansion.
Overall, Castle Biosciences' Q2 performance reflects a resilient and promising trajectory, underpinned by strategic strengths and a commitment to advancing patient care.

Castle Biosciences excels in Q3, poised for sustained growth

Castle Biosciences' Q3 performance reflects strong revenue growth, financial stability, and a positive outlook for future expansion.
The company's focus on product innovation, market penetration, and financial discipline positions it well for continued success.
While challenges exist in maintaining growth and profitability, Castle Biosciences has ample opportunities for further market expansion and value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DecisionDxMelanoma--Castle Biosciences announced the launch of the Company's inaugural Environmental, Social and Governance (ESG) report.

Castle Biosciences Releases Inaugural Environmental, Social and Governance (ESG) Report

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DecisionDxMelanoma--Castle announced the publication of a study validating performance of the i31-SLNB algorithm to determine sentinel lymph node biopsy positivity risk.

Castle Biosciences Publishes DecisionDx®-Melanoma Study on the Validation of the i31-GEP SLNB Artificial Intelligence Algorithm

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DecisionDxMelanoma--Castle Biosciences announced its agreement with ModMed to establish an interface with ModMed's electronic health records system, EMA®.

Castle Biosciences' Full DecisionDx® Portfolio of Dermatologic Tests to Be Interfaced with EMA® Electronic Health Records System

Castle Biosciences, Inc. (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Castle Biosciences, Inc. (CSTL) to Report a Decline in Earnings: What to Look Out for

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DecisionDxMelanoma--Castle announced that the Company's DecisionDx®-Melanoma integrated test result (ITR) now includes i31-GEP for Risk of Recurrence (i31-ROR).

DecisionDx®-Melanoma Integrated Test Result Now Includes i31-GEP for Risk of Recurrence

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DecisionDxDiffDxMelanoma--Castle announced a recent poster presentation on its DecisionDx® DiffDx™-Melanoma test at the ASDP 58th Annual Meeting.

New Data Demonstrating Accuracy of DecisionDx® DiffDx™-Melanoma Presented at ASDP 58th Annual Meeting

PITTSBURGH, Oct. 25, 2021 /PRNewswire/ -- Pittsburgh Life Science Greenhouse (PLSG) is proud to share that one of its portfolio companies, Cernostics, Inc., is being acquired by Castle Biosciences (Nasdaq: CSTL). Cernostics specializes in spatial biology and artificial intelligence-driven image analysis of tissue biopsies.

Pittsburgh Life Sciences Greenhouse Proudly Announces Portfolio Company Cernostics is Being Acquired by Castle Biosciences

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DecisionDxMelanoma--Castle will release its financial results for the third quarter and nine months ended Sept. 30, 2021, after the close of market on Nov. 8, 2021.

Castle Biosciences to Release Third Quarter 2021 Financial Results and Host Conference Call on Monday, Nov. 8, 2021

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DecisionDxDiffDxMelanoma--Castle announced data presentations on the Company's dermatologic GEP tests at the 2021 Fall Clinical Dermatology Conference, held Oct. 21-24.

Castle Biosciences Presents Data from Suite of Dermatologic Cancer Genomic Tests at Fall Clinical Dermatology Conference 2021

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #BarrettsEsophagus--Castle Biosciences today announced it has signed a definitive agreement to acquire Cernostics, Inc.

Castle Biosciences to Acquire Cernostics

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #AZBio--Derek Maetzold, president and chief executive officer of Castle Biosciences, will deliver the keynote presentation during Arizona Bioscience Week.

Castle Biosciences President and CEO Derek Maetzold Will Deliver Keynote Presentation During Arizona Bioscience Week

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DecisionDxDiffDxMelanoma--Castle Biosciences has received approval from the New York State Department of Health for its DecisionDx® DiffDx™-Melanoma GEP test.

Castle Biosciences Announces New York Approval of DecisionDx® DiffDx™-Melanoma

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DecisionDxMelanoma--Castle Biosciences has been included in The Healthcare Technology Report's Top 100 Healthcare Technology Companies of 2021 list.

Castle Biosciences Recognized as a Top 100 Healthcare Technology Company of 2021

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced that it has been awarded a five-year U.S. Federal Supply Schedule (FSS) contract for its DecisionDx®-Melanoma test.

Castle Biosciences Awarded U.S. Federal Supply Schedule Contract for DecisionDx-Melanoma

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DecisionDxMelanoma--Castle Biosciences announced recent presentations on two of its skin cancer GEP tests at the 2021 American Academy of Dermatology Summer Meeting.

Castle Biosciences Presents New Data on DecisionDx®-Melanoma and DecisionDx®-SCC at the 2021 American Academy of Dermatology (AAD) Summer Meeting

Castle Biosciences, Inc (CSTL) CEO Derek Maetzold on Q2 2021 Results - Earnings Call Transcript

After the market close on Monday, Castle Biosciences Inc (NASDAQ: CSTL) reported that its second-quarter revenues rose 79% Y/Y to $22.75 million, beating the consensus of $18.93 million. The increase was attributable to more than double the number of tests delivered during the quarter.

Castle Biosciences Q2 Earnings Edges Out Expectation On Record Test Report Volume

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle today announced its financial results for the second quarter and six months ended June 30, 2021.

Castle Biosciences Announces Second Quarter 2021 Results

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DecisionDxMelanoma--Castle Biosciences announced oral data presentations on two of its skin cancer gene expression profile tests during the 2021 AAD Summer Meeting.

Castle Biosciences to Present Data at the 2021 American Academy of Dermatology (AAD) Summer Meeting

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DecisionDxMelanoma--Castle announced data presentations on two of its skin cancer GEP tests at the DEF Essential Resource Meeting (DERM2021) NP/PA CME Conference.

Castle Biosciences Presents Data on DecisionDx®-Melanoma and DecisionDx®-SCC at the DERM2021 NP/PA CME Conference

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DecisionDxMelanoma--Castle today announced its continued collaboration with the Melanoma Research Foundation (MRF).

Castle Biosciences Collaborates with the Melanoma Research Foundation

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #castlebiosciences--Castle Biosciences is scheduled to present a company overview at the Canaccord Genuity 41st Annual Growth Conference.

Castle Biosciences to Participate at the Canaccord Genuity 41st Annual Growth Conference

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #castlebiosciences--Castle Biosciences announced that it will release its financial results for the second quarter and six months ended June 30, 2021 on Aug. 9, 2021.

Castle Biosciences to Release Second Quarter 2021 Financial Results and Host Conference Call on Monday, Aug. 9, 2021

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #AHNS--Castle Biosciences announced a podium presentation at the American Head & Neck Society (AHNS) 10th International Conference on Head and Neck Cancer.

Castle Biosciences Presents New Data Demonstrating DecisionDx®-SCC Complements Current Risk Assessment Methods in Patients with Cutaneous Squamous Cell Carcinoma of the Head and Neck

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #SDPA--Castle Biosciences announced data presentations at the Society of Dermatology Physician Assistants (SDPA) Annual Summer Dermatology Conference 2021.

News for Castle Biosciences Inc Stock (CSTL)